Exelixis, Inc. Hits New 52-Week High of $52.98, Surging 138%

Exelixis, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 52.98 on June 5, 2026. This achievement underscores the company's robust performance, as it has delivered an impressive 138.14% return over the past year, significantly outpacing the S&P 500's 24.32% gain during the same period. The company's financial metrics reflect strong fundamentals, with a price-to-earnings (P/E) ratio of 14.00 and a return on equity (ROE) of 36.94%. Exelixis has demonstrated healthy growth, with net sales increasing at an annual rate of 18.63% and a net profit growth of 31.86%. The company has also reported positive results for three consecutive quarters, showcasing its operational strength. With a market capitalization of USD 10,786 million and a net-debt-free status, Exelixis is well-positioned in the market. Its price-to-book ratio stands at 4.99, indicating an attractive valuation relative to its peers. The stock's performance continues to reflect its strong long-term growth potential and solid financial health.